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Abstract: In pre-hospital care, an accurate and quick diagnosis of ST-segment elevation myocardial
infarction (STEMI) is imperative to promptly kick-off the STEMI network with a direct transfer to the
cardiac catheterization laboratory (cath lab) in order to reduce myocardial infarction size and mortality.
Aa atherosclerotic plaque rupture is the main mechanism responsible for STEMI. However, in a small
percentage of patients, emergency coronarography does not reveal any significant coronary stenosis.
The fluoropyrimidine agents such as 5-Fluorouracil (5-FU) and capecitabine, widely used to treat
gastrointestinal, breast, head and neck cancers, either as a single agent or in combination with other
chemotherapies, can cause potentially lethal cardiac side effects. Here, we present the case of a patient
with 5-FU cardiotoxicity resulting in an acute coronary syndrome (ACS) with recurrent episodes of
chest pain and ST-segment elevation.. Our case report highlights the importance of widening the
knowledge among cardiologists of the side effects of chemotherapeutic drugs, especially considering
the rising number of cancer patients around the world and that fluoropyrimidines are the main
treatment for many types of cancer, both in adjuvant and advanced settings.
Keywords: 5-Fluorouracil; acute myocardial infarction; acute coronary syndrome; ST-segment
elevation myocardial infarction—STEMI; coronary spasm; myocardial enzymes; troponin I; chest
pain; cardiotoxicity
1. Introduction
Fluoropyrimidine agents such as 5-FU and capecitabine are extensively used in the
palliative and adjuvant treatment of numerous solid tumors. In addition to systemic
applications, 5-FU is often used topically for the treatment of various skin conditions.
A large body of research indicates that the toxicity induced by these two fluoropyrim-
idines is probably dose-dependent and mainly due to the efficiency of the dihydropyrimi-
dine dehydrogenase (DPYD), which is the enzyme that catalyze 5-FU degradation [1,2].
Usually fluoropyrimidine toxicity is manageable, consisting of mild nausea, vomiting,
diarrhea and myelosuppression [1]. A less frequent and underestimated complication, is
cardiotoxicity [3]. Polymorphisms of DPYD and pre-existing heart disease are the main
factors influencing the incidence of cardiotoxicity [1,4]. Cardiotoxicity could manifest as
angina pectoris, myocardial infarction, atrial and ventricular arrhythmias, hypertension,
hypotension, dilated cardiomyopathy and heart failure.
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Interestingly, 5-FU-induced coronary vasospasm can result in all forms of ACS, in-
cluding transient and persistent ST-segment elevation. After the suspension of the 5-FU, its
re-introduction should be specifically made on a case-by-case basis for each patient. In par-
ticular, it can be proposed in association with CCBs prophylaxis and telemetry monitoring
for younger patients in a context of curative chemotherapy.
Here, we present a case of an 80-year-old man with an intermittent ST-segment
elevation ACS after treatment with 5-FU.
2. Case Presentation
An 80-year-old man, non-smoker, with a history of grade 1 hypertension and a known
left bundle branch block (LBBB) was directly transferred to the catheterization laboratory
(cath lab), bypassing the Emergency Department (ED) for urgent coronary angiography,
due to severe, prolonged chest pain irradiating to the left arm and associated with the
presence of ST-elevation over inferior and lateral leads, in addition to the known LBBB at
pre-hospital electrocardiogram (EKG) (Figure 1). The patient had no other cardiovascular
risk factors and was not taking any cardiovascular medication.
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4000 U were also administered during the ambulance transfer. 
During the preparation for the procedure in the cath lab, the patient’s pain subdued. 
The emergency coronary angiogram did not reveal any hemodynamically significant 
stenosis of the coronary tree (Figure 2). There was a focal 40% stenosis of the first diagonal 
and a 40% focal stenosis of proximal circumflex artery, which were considered not hemo-
dynamically significant. 
Figure 1. First EKG recorded by 118 (markedly agitated patient), sinus rhythm, left bundle branch block, inferolateral
subepicardial lesion.
The patient reported that a few hours before the admission he had experienced a
transient episode of chest pain which he had attributed to muscle strain.
Upon arrival, he appeared uncomfortable, but no signs of pulmonary congestion were
detected, with the rest of the cardiovascular examination appearing normal. Forty-eight
hours before admission the patient had begun first line chemotherapy with a modified
FOLFOX regimen (consisting of a combination of 5-FU, Leucovorin and Oxaliplatin admin-
istered as in-hospital bolus, plus 46 h of continuous infusion through Port-a-Cath, every
two-weeks) to treat a stage IV colorectal cancer with hepatic metastasis. The patient’s
vitals were stable: blood pressure at 125/85 mmHg, heart rate of 65 beats per minute,
respiratory rate of 16 breaths per minute, oxygen saturation at 99% while breathing in
ambient air. A dual antiplatelet therapy with a loading dose of acetylsalicylic acid (250 mg),
ticagrelor (180 mg) along with an intravenous (iv) bolus of heparin sodium 4000 U were
also administered during the ambulance transfer.
During the preparation for the procedure in the cath lab, the patient’s pain subdued.
The emergency coronary angiogram did not reveal any hemodynamically significant steno-
sis of the coronary tree (Figure 2). There was a focal 40% stenosis of the first diagonal and a
40% focal stenosis of proximal circumflex artery, which were considered not hemodynami-
cally significant.
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biventricular systolic function. 
Unfortunately, the infusion of 5-FU was not suspended and approximately one hour 
after his admission to ICCU, the cardiac intensivist had to be called in because the patient 
was experiencing another episode of intense chest pain. On 12 lead EKG (Figure 4) as well 
as on EKG-telemonitoring, sinus rhythm, LBBB and inferolateral subepicardial ischemia 
were detected. A transthoracic echocardiogram showed a mild reduction in left 
ventricular function with an ejection fraction (EF) of 43% and hypokinesis of inferior, 
septal and apical walls. 
Figure 2. Cardiac catheterization. Right anterior oblique, (a) caudal and (b) cranial of left coronary anatomy (stenosis
40% on the first di gonal). Left anterior oblique, (c) cranial of right coronary natomy (ste osis 50% on th proximal
right coronary).
EKG performed afterwards showed normal sinus rhythm with LBBB, without ST-
segment abnormalities that could indicate ischemia (Figure 3).
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Figure 3. EKG after emergent coronar graphy; sinus rhythm, eart rate 55 bpm, LBBB, ST normalization.
The patient was transferred to the Intensive Cardiac Care Unit (ICCU) for further care
and monitoring. Transthoracic echoc r iography showed overall normal biventricular
systolic functio .
Unfortunately, the infusion of 5-FU was not suspended and approximately one hour
after his admission to ICCU, the cardiac int nsivist had to be ca led in because the patient
was experiencing another episode of intense chest pai . On 12 lead EKG (Figure 4) as well
as o EKG-telemonitoring, sinus rhythm, LBBB and inferolate al subepicardial ischemia
were detected. A transt oracic echocardiogram showed a mild reduction in left ventricular
function with n ej cti n fraction (EF) f 43% and hypokinesis of inf rior, septal and
apical alls.
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Figure 5. EKG after diltiazem administration.
Once the atient’ symptoms stabilized following the iv therapy, diltiazem was orally
administered at a l wer dose of 30 mg, thr e times per day due to the patient’s relatively
low heart rate. The dosage diltiazem was therefore up-titrated o the maximum tolerated
dose of 60 mg every 8 h, with a gradual reduction and omplete disapp arance of angina
attacks (during the fi st 2 days in ICCU he experienc d thr e pisodes of chest pain
assoc ated w th ST segment el vation in inferolateral eads). High ensitivity troponin
did ot increase significa tly over ime (peak tro onin level 28 ng/L) and other standard
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laboratory tests showed results within normal thresholds (hemoglobin 12.8 g/dl, platelet
count 237,000/mmc, glycemia 118 mg/dl, serum creatinine 0.91 mg/dl, serum sodium
139 mEq/l, serum potassium 3.86 mEq/l). No arrhythmias were recorded during ICCU stay.
He was discharged after six days. Taking into consideration the patient’s age, palliative
chemotherapy aim and the high risk of relapsing myocardial ischemia, re-challenge with
5-FU was not performed and an alternative chemotherapy regimen was started instead. At
six months follow-up the patient reported no chest pain relapses nor echocardiographic
changes were detected, therefore no other exams were planned.
3. Discussion
3.1. Indications for 5-FU
Fluoropyrimidine agents, such as 5-FU and Capecitabine, are widely used in the
palliative and adjuvant treatment of several solid tumors. Labeled indications include
gastrointestinal, breast, head and neck cancers, either as a single agent or in combination
with other chemotherapies. Beyond the Food and Drug Administration (FDA)-approved
indications, 5-FU is frequently employed off-label in hepatic and genitourinary cancers.
In addition to systemic applications, 5-FU is often used topically for the treatment
of various skin conditions [3]. Approved by the FDA for the treatment of actinic or
solar keratoses and superficial basal cell carcinoma, topical 5-FU has also demonstrated
efficacy in cutaneous melanoma metastases, keratoacanthoma and conventional treatment-
resistant vitiligo.
3.2. 5-FU Toxicity and Risk Stratification
Usually, fluoropyrimidine toxicity is manageable, consisting of mild nausea, vomiting,
diarrhea and myelosuppression, except for DPYD polymorphisms [5]. The DPYD gene
encodes for an enzyme that catalyzes the rate-limiting step in fluorouracil catabolism,
so that some DPYD genetic variants can lead to a decreased enzymatic activity, with
implications in terms of toxicity. Therefore, Iachetta et al. have suggested a systematic
DPYD genotyping before the onset of chemotherapy [6]. The stratification of patients on the
basis of the DPYD genotype may prevent such adverse events, through the administration
of a reduced dose of the chemo-drug in patients who are carriers of pathogenic variants.
A routine pre-treatment screening of deleterious DPYD polymorphisms is rarely
adopted in clinical practice, although the main current guidelines of the Clinical Phar-
macogenetics Implementation Consortium have identified the four clearly pathogenic
variants associated with 5-FU toxicity [7]. These DPYD polymorphisms (c.1905 + 1G > A,
rs3918290; c.2846A > T, rs67376798; c.1679T > G; rs55886062 and c.1236G > A, rs56038477),
which are the most commonly observed in the Indo-European population, can be de-
tected using LAMP Human DPD deficiency kit (LaCAR MDx Technologies). Moreover,
genotypic tests for DPYD variants before 5-FU administration may be cost-effective: in a
large-scale analysis, Deenen et al. show that upfront genotyping of DPYD*2A variant—also
known as rs3918290—is feasible and cost-saving [8]. Indeed, DPYD*2A is the most relevant
polymorphism responsible for DPYD deficiency and its prevalence is 1% to 2% in the
Western population [9], so that screening costs are substantially offset by the reduction in
toxicity-related patient charges.
A less frequent and underestimated, but potentially lethal side effect, is cardiotox-
icity [10]. For example, in this case report, the diagnosis of 5-FU induced vasospasm
was at first overlooked by the cardiologist on call and the initial management included
an emergency coronary angiography. To date no clear risk factors are known to predict
and prevent cardiotoxicity in “healthy” patients and the reported incidence of this side
effect can range from 4% to 30.6%, according to reports from oncologists and cardiologists,
respectively [11,12]. On the other side, pre-existing heart disease and an impaired renal
function seem to be the most important risk factors associated with 5-FU cardiotoxicity [4],
without forgetting the role of genetic susceptibility.
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Another controversial topic about 5-FU toxicity concerns combination treatments:
could 5-FU toxicity be enhanced by other chemo-drugs or radiotherapeutic treatment?
While Labianca et al. found that the concomitant treatment with other chemo-drugs,
such as vincristine, cyclophosphamide and methotrexate did not alter the incidence of
5-FU cardiotoxicity [13], in another study the association among capecitabine, oxaliplatin
and bevacizumab led to higher risks of cardiotoxicity if compared with capecitabine
monotherapy [14]. Oxaliplatin, used in conjunction with 5-FU in our patient, is not known
to cause such side effects on its own, but there is the possibility it might have enhanced
5-FU cardiotoxicity. Regarding radiation therapy, the previous myocardial irradiation was
proposed as an additional risk factor of 5-FU cardiotoxicity [15].
Lastly, the dose dependence of 5-FU-related cardiotoxicity is an area of ongoing
debate [2], even though circulating FU levels seemed not to correlate with cardiovascular
side effects in a study by Thyss et al. [16]. On the contrary, a relationship between the
dosage of 5-FU and other FU-associated toxicities has been documented, for example,
where the severity of intestinal injury is associated with the dosage of 5-FU in a murine
model [17].
3.3. 5-FU Cardiotoxicity from a Clinical Point of View
Cardiotoxicity could manifest itself as angina pectoris, atrial and ventricular arrhyth-
mias, hypertension, hypotension, dilated cardiomyopathy and chronic heart failure. Acute
heart failure remains a relatively rare occurrence [18], even if occasional cases of cardio-
genic shock are reported in literature [19]. However, left ventricular dysfunction, including
echocardiographic views that copy Takutsubo syndrome, may often be observed [20,21].
Some recent reports even describe cases of severely reduced ejection fraction recognized
accidentally during the diagnostic workup, in which the patient did not experience any
symptoms or signs [22]. These reports emphasize the importance of close monitoring
during the first phase following 5-FU therapy. In fact, an acute left ventricular systolic
dysfunction, although asymptomatic and reversible, increases the risk for complications
like thrombus formation and fatal arrhythmias.
The monitoring should include at least an EKG and the assessment of serum biomark-
ers of myocardial injury. In particular, the evaluation of N-terminal pro-brain natriuretic
peptide (NT-proBNP) may facilitate safer applications of this cardiotoxic drug [23]. NT-
proBNP elevation, generally associated with hemodynamical stress caused by contractility
abnormalities, could also be the result of a direct toxic effect on myocardial cells. How-
ever, a normal level of NT-proBNP, as for the other common biomarkers of cardiac injury
(troponin and creatine phosphokinase), does not rule out cardiotoxicity, showing a low
negative predictive value [24].
Moreover, EKG changes and arrhythmias can also occur in asymptomatic patients [25–27].
Both silent repolarization and rhythm disorders pose an important management challenge
for the cardiologist, due to their unclear clinical significance.
Fortunately, the cardiac adverse effects of fluoropyrimidines can be usually reversed
through the discontinuation of the treatment [28–31].
3.4. Underlying Pathogenic Mechanisms
According to the available literature, the most common manifestation of 5-FU-induced
cardiotoxicity is myocardial ischemia, usually occurring at rest and characterized by ST
segment elevation following coronary vasospasms. Well-documented reported cases
of acute coronary syndrome (ACS) due to spasm (proved or likely) in the setting of
fluoropyrimidine use are summarized in Table 1.
The relevance of this pathogenic mechanism of acute coronary syndrome in sev-
eral patients receiving 5-FU is supported by coronary angiography (not infrequently ev-
idence of normal coronaries [32–35] and occasionally a direct visualization of coronary
spasms) [36,37] and clinical course (a sudden onset and rapid recovery from symptoms,
transitory ischemic changes in EKG, responsiveness to anti-spasmogenic therapy).
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As in the case described above, the symptoms and instrumental abnormalities are
solved through the discontinuation of fluoropyrimidine drug treatment together with
diltiazem administration, even if they transiently reappear in the following days in accor-
dance with the disposal time of 5-FU [38,39]. Therefore, patients need to continue intensive
monitoring for several days after withdrawal. To date, it is known that 5-FU plasma’s
half-life is relatively short (around 4 h) since it is catabolized by liver enzymes, especially
DPYD. Nevertheless, it does not avoid tissue accumulation, leading to the formation of
active 5-FU metabolites, which explains the long-lasting cytotoxicity [40]. The mechanisms
of 5-FU induced cardiotoxicity are not completely understood and coronary vasospasm
seems to be the most well documented manifestation [41,42].
The mechanism behind spasms is complex and still unclear, but it is likely linked to an
endothelial dysfunction with imbalances between local vasoconstrictors and vasodilators
(Figure 6). For example, increased plasma levels of endothelin-1 were detected in patients
receiving 5-FU [43,44], whereas the deficiency in nitric oxide amplified the hyperreactivity
of cardiac arteries [45]. In addition, an endothelium-independent mechanism has been hy-
pothesized, demonstrating in vitro protein kinase C-mediated vasoconstriction of vascular
smooth muscles [42]. However, in some patients abnormalities of the left ventricular wall
motion have been reported in areas not corresponding to coronary vessel distribution, sug-
gesting a multifactorial cardiotoxicity mechanism: the occurrence of ischemia, secondary to
coronary vasospasms, is only a component of the pathophysiological spectrum, which also
includes the thrombosis of small vessels, direct toxicity on the myocardium and inflam-
mation that could lead to myocarditis [46]. For example, Calik et al. described an original
case of acute toxic myopericarditis occurring after the first bolus dose of 5-FU [47]. Their
patient, admitted to the ICCU with clinical features similar to ours, presented however
inflammatory biomarkers elevation and echocardiography revealed global myocardial
hypokinesia of the left ventricle. Therefore, she was treated with ibuprofen, metoprolol
and ramipril and discharged without any problems, showing a complete normalization of
systolic function after 2 months.
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Table 1. Previously well-documented described cases of ACS following coronary spasm (proved or likely) associated with fluoropyrimidine use. Differences in echocardiographic features
and troponin levels are probably attributable to differences in coronary spasm extension and duration, even though other concomitant pathophysiological causes, such as myocardial
inflammatory injury and vascular endothelial dysfunction, cannot be ruled out.
Luwaert et al. [36] Camaro et al. [34] Dalzell and Samuel [48] Atar et al. Patient 1 [33] Atar et al. Patient 2 [33] Shah et al. [37] Dechant et al. [18]
























CHEMOTHERAPY Carboplatin None Oxaliplatin, leucovorin Folinic acid Folinic acid None Non reported
MODE OF
ADIMINISTRATION 5-FU infusion Oral capecitabine 5-FU infusion 5-FU infusion 5-FU infusion Oral capecitabine 5-FU bolus + infusion
DOSE 1000 mg/m2/day 1500 mg/m2 twice daily NR 425 mg/m2/day 425 mg/m2/day 1250 mg/m2 twice daily




SYMPTOMS Angina pectoris Retrosternalchest pain Typical chest pain Chest pain Chest pain
Cardiac arrest
(ventricular fibrillation) Typical chest pain
TIMING OF ONSET
SYMPTOMS Day 3 Day 1 20 h into the infusion Day 3 Day 3
5 of a total of 6 cycles of
chemotherapy Day 2










leads II, III, aVF, V5 and
V6
ST-segment elevation in






and prominent T waves
in almost all leads (I–III,
aVF and V2–V6)
TROPONIN Not reported Normal Elevated Normal Normal Elevated Not reported
















coronary flow. after 2
days normal coronaries.
INTERVENTION Diltiazem and nitrate Nifedipine Ramipril, Metoprolol Diltiazem Diltiazem and Nitrate Verapamil, defibrillator ACE inhibitor,Verapamil, diuretics
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The evidence that some patients develop global electrocardiographic changes and
generalized left ventricular hypokinesia suggests the possibility of a 5-FU induced global
myocardial abnormality.
Sometimes more pathogenic mechanisms can coexist: Dalzell and Samuel describe a
case of 5-FU cardiotoxicity where symptoms and instrumental findings cannot be explained
either by coronary spasm or by myocarditis alone [48].
A 5-FU induced increase in reactive oxygen species (ROS) has also been documented.
Focaccetti et al. examined the effects of 5-FU on cell cultures of human cardiomyocytes and
endothelial cells, observing that ROS elevation characterized the endothelial response [49].
3.5. Management of 5-FU Acute Coronary Syndrome with ST Segment Elevation
Based on these pathophysiological considerations, calcium channel antagonists appear
very useful in the context of coronary spasms, in particular non-dihydropyridine calcium
channel blockers (CCBs). In the hypothesis of coronary vasospasm with patients receiving
treatment with fluoropyrimidine agents, the administration of CCBs and nitrates should
be considered as a first-line ex juvantibus treatment in a pre-hospital setting, as well as in
spoke hospitals, before transferring the patients to the hub center for emergency coronary
imaging (Figure 7). Clearly, as demonstrated by our case, the tendency to bradycardia could
represent a limit to both the introduction and up-titration of CCBs. However, in the case
of excessive bradycardia with diltiazem or verapamil, a shorter-acting substance such as
the dihydropyridine nifedipine should be tested instead. On the other hand, beta-blockers
should be avoided in these patients due to their spasmogenic power.
In any case, in the context of ST-segment elevation myocardial infarction (STEMI),
cardiac catheterization remains an overriding exam: the absence of obstructive atheroma-
tous coronary artery disease will strengthen the association among clinical features and
chemotherapy. On the other side, a wrong attribution of the clinical picture to chemotherapy
can lead incorrectly to a discontinuation of the drug, compromising the cancer treatment.
Even though most cases of cardiac side effects of 5-FU improve spontaneously, recur-
rence is possible when the drug is administered again to the same patient. From this point
of view, two important issues should be discussed: prophylactic treatment and re-challenge
with 5-FU.
Coronary spasm being the most common physiopathological mechanism behind 5-FU
cardiotoxicity, the possible usefulness of a spasm provocation test with ergonovine (ER) or
acethilcoline (Ach) could be imagined. However, these tests are not strongly recommended
in current ESC guidelines and should be limited to selected patients [50]. In our case,
since symptoms and EKG alterations had resolved after 5-FU withdrawal and diltiazem
treatment, an “ex adjuvantibus” diagnosis was made according to the clinical context,
without the need for provocative tests. Furthermore, with the benefit of hindsight, the
spasm provocation test would have probably exposed the patient to a significant additional
risk in the acute phase, since ER and Ach could cause life-threatening side effects [51],
potentially exacerbated in combination with 5-FU. Finally, as stated above, coronary spasm
is not the only mechanism of 5-FU cardiotoxicity. Therefore, we can speculate a negative
coronary spasm test to be not enough to rule out 5-FU cardiotoxicity. Accordingly, in view
of all these considerations, a provocative test for coronary artery spasm was not deemed
appropriate for this patient.
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3.6. Profilaxis
The prophylactic role of calcium channels has been studied but its exact role is still
debated. In a study from Eskilsson and Albertsson, the prophylactic verapamil was used
on 58 patients treated with 5-FU for es phageal, head and n ck cancers [52]. In this study
Verapamil did not reduce the insurgence f myocar ial is hemia during c emoth rapy
treatment. However, if compared to the historical control, it seemed to be useful in
preventing arrhythmias, which have been associated with a more malignant course.
In another study the administration of nitrates and/or calciu channel blockers
failed to prevent recurrence of 5-FU cardiotoxicity [53]. These results do not rule out the
possibility of coronary artery spasm but suggest a heterogeneous response to a vasodilator
Pharmaceuticals 2021, 14, 563 11 of 14
among patients. After all, as stated above, several mechanisms other than spasm may
underpin 5FU-cardiotoxicity, thus explaining the inefficacy of a vasodilator.
In a few cases, the positive effects of calcium channel blockers prophylactic treatment
have been reported, but the dosage and right timing of the administration still have to be
investigated [54]. Furthermore, some calcium channel blockers such as nifedipine may be
dangerous, for example, enhancing the toxic effects of concomitant chemo-drugs [55].
3.7. Re-Challenge with 5-FU
Another controversial issue concerns the potential re-challenge with 5-FU: studies have
shown that the drug’s re-introduction after 5-FU-induced ACS can be successful [55–58].
However, the choice of attempting a re-challenge should be specifically made on a case-by-
case basis for each patient. In particular, it can be proposed in association with CCBs prophy-
laxis and telemetry monitoring for younger patients in a context of curative chemotherapy.
For what concerns our patient, the risk/benefit ratio did not justify the adoption of
this therapeutic option, therefore alternative treatments were chosen [59].
4. Take Home Message
Knowledge advancements and the increasing complexity of care specialization have
led to many points of contact between different branches of medicine. In the context
of a multifaceted healthcare system, a teamwork approach is crucial to improve patient
safety and overall outcome. Our case report highlights the importance of broadening
the understanding among cardiologists of chemotherapeutic drugs’ side effects. Thus, if
life-threatening cardiac injury from chemotherapy is suspected, the treatment should be
suspended as soon as possible. Furthermore, in these cases an ex juvantibus treatment with
CCBs and nitrates should be considered before any emergency coronary angiography.
5. Conclusions
This is a well-documented case of cardiotoxicity induced by fluoropyrimidine upon
first administration in a patient with few cardiovascular risk factors. We strongly believe
that all patients who receive fluoropyrimidines should be notified about the possibility of
this type of toxicity and should be thus prompted to report symptoms to an oncologist
in order to avoid major complications. The knowledge of the potential cardiotoxic effects
of chemotherapeutic drugs is fundamental for every cardiologist in order to raise the
clinical suspicion of cardiotoxicity. Moreover, a detailed discussion with the oncologist
must be encouraged in order to evaluate the risk/benefit ratio of the treatment and any
alternative option.
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